Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia

Blood. 2012 Aug 16;120(7):1529-31. doi: 10.1182/blood-2012-06-433821.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Cell Transformation, Neoplastic / drug effects*
  • Cell Transformation, Neoplastic / pathology*
  • Chromosomes, Human, Pair 8 / genetics
  • Chromosomes, Human, Pair 9 / genetics
  • Cytogenetic Analysis
  • Humans
  • Hypereosinophilic Syndrome / drug therapy
  • Hypereosinophilic Syndrome / genetics*
  • Janus Kinase 2 / metabolism*
  • Male
  • Nitriles
  • Oncogene Proteins, Fusion / metabolism*
  • Pyrazoles / pharmacology*
  • Pyrazoles / therapeutic use
  • Pyrimidines
  • Remission Induction
  • Translocation, Genetic / drug effects*

Substances

  • Nitriles
  • Oncogene Proteins, Fusion
  • PCM1-JAK2 fusion protein, human
  • Pyrazoles
  • Pyrimidines
  • ruxolitinib
  • Janus Kinase 2